Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma
NCT03266757 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2019-04-05
Summary
Observational study of the Clinical Practice in patients with Borderline resectable or resectable or advanced pancreatic adenocarcinoma.
Conditions
- Pancreatic Adenocarcinoma
Sponsors & Collaborators
-
Hellenic Society of Medical Oncology
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-11
- Primary Completion
- 2017-02-11
- Completion
- 2018-02-11
More Related Trials
-
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
NCT03822936 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
NCT05825066 ·Status: RECRUITING ·Phase: PHASE2
-
Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and Borderline
NCT05514171 ·Status: COMPLETED
-
Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer
NCT02717091 ·Status: UNKNOWN ·Phase: PHASE2
-
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
NCT02072616 ·Status: TERMINATED ·Phase: NA
-
Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer
NCT05356039 ·Status: RECRUITING
-
The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
NCT02296736 ·Status: COMPLETED
-
Proteomic Profiling to Differentiate Pancreatic and Biliary Adenocarcinomas
NCT06776146 ·Status: NOT_YET_RECRUITING
-
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
NCT04835064 ·Status: UNKNOWN ·Phase: PHASE3
-
PAncreas Borderline and Locally Advanced Snapshot Study
NCT05470738 ·Status: UNKNOWN
-
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
NCT06435260 ·Status: RECRUITING ·Phase: PHASE2
-
Management of Symptomatic Advanced Pancreatic Adenocarcinoma
NCT02979483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
NCT02459652 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection
NCT02750657 ·Status: COMPLETED
-
Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma
NCT05248750 ·Status: RECRUITING
-
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
NCT01531712 ·Status: TERMINATED ·Phase: PHASE2
-
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
NCT00761241 ·Status: COMPLETED ·Phase: PHASE2
-
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
NCT02723331 ·Status: COMPLETED ·Phase: PHASE2
-
Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC
NCT04855331 ·Status: RECRUITING ·Phase: NA
-
Neoadjuvant Treatment in Resectable Pancreatic Cancer
NCT01900327 ·Status: TERMINATED ·Phase: PHASE3
-
Proton Radiation for Resectable Carcinoma of the Pancreas
NCT00763516 ·Status: COMPLETED ·Phase: NA
-
Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
NCT04466189 ·Status: ENROLLING_BY_INVITATION
-
Prognostic and Predictive Markers of Treatment Response in Patients With PAC.
NCT05776342 ·Status: RECRUITING
-
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
NCT02850874 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
NCT01240304 ·Status: TERMINATED ·Phase: PHASE2